290 related articles for article (PubMed ID: 15680290)
1. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.
Rosenberg R; Caron J; Roth T; Amato D
Sleep Med; 2005 Jan; 6(1):15-22. PubMed ID: 15680290
[TBL] [Abstract][Full Text] [Related]
2. A polysomnography study of eszopiclone in elderly patients with insomnia.
McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T
Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566
[TBL] [Abstract][Full Text] [Related]
3. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
Najib J
Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.
Roth T; Walsh JK; Krystal A; Wessel T; Roehrs TA
Sleep Med; 2005 Nov; 6(6):487-95. PubMed ID: 16230048
[TBL] [Abstract][Full Text] [Related]
5. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
8. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.
Walsh JK; Mayleben D; Guico-Pabia C; Vandormael K; Martinez R; Deacon S
Sleep Med; 2008 May; 9(4):393-402. PubMed ID: 17765013
[TBL] [Abstract][Full Text] [Related]
10. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness.
Walsh JK; Salkeld L; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2010 Jan; 11(1):23-30. PubMed ID: 19945340
[TBL] [Abstract][Full Text] [Related]
11. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
Boyle J; Trick L; Johnsen S; Roach J; Rubens R
Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566
[TBL] [Abstract][Full Text] [Related]
12. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Soares CN; Joffe H; Rubens R; Caron J; Roth T; Cohen L
Obstet Gynecol; 2006 Dec; 108(6):1402-10. PubMed ID: 17138773
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
Zammit GK; McNabb LJ; Caron J; Amato DA; Roth T
Curr Med Res Opin; 2004 Dec; 20(12):1979-91. PubMed ID: 15701215
[TBL] [Abstract][Full Text] [Related]
14. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia.
Walsh JK; Zammit G; Schweitzer PK; Ondrasik J; Roth T
Sleep Med; 2006 Mar; 7(2):155-61. PubMed ID: 16260179
[TBL] [Abstract][Full Text] [Related]
15. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia.
Walsh JK; Perlis M; Rosenthal M; Krystal A; Jiang J; Roth T
J Clin Sleep Med; 2006 Jan; 2(1):35-41. PubMed ID: 17557435
[TBL] [Abstract][Full Text] [Related]
16. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
Pollack MH; Hoge EA; Worthington JJ; Moshier SJ; Wechsler RS; Brandes M; Simon NM
J Clin Psychiatry; 2011 Jul; 72(7):892-7. PubMed ID: 21367352
[TBL] [Abstract][Full Text] [Related]
17. Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized crossover comparative study with brotizolam.
Uchimura N; Nakajima T; Hayash K; Nose I; Hashizume Y; Ohyama T; Habukawa M; Kotorii N; Kuwahara H; Maeda H
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):22-9. PubMed ID: 16048734
[TBL] [Abstract][Full Text] [Related]
18. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study.
Dorsey CM; Lee KA; Scharf MB
Clin Ther; 2004 Oct; 26(10):1578-86. PubMed ID: 15598474
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
Krystal AD; Walsh JK; Laska E; Caron J; Amato DA; Wessel TC; Roth T
Sleep; 2003 Nov; 26(7):793-9. PubMed ID: 14655910
[TBL] [Abstract][Full Text] [Related]
20. The effects of ramelteon in a first-night model of transient insomnia.
Zammit G; Schwartz H; Roth T; Wang-Weigand S; Sainati S; Zhang J
Sleep Med; 2009 Jan; 10(1):55-9. PubMed ID: 18691937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
